Constitutive activation of epstein-barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency

Molecular and Cellular Biology

Volumn 17, Issue 2, 1997, Pages 873-886

  Schaefer, Brian C ^a,c   Paulson, Emily ^b   Strominger, Jack L ^a   Speck, Samuel H ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL NUCLEUS ANTIGEN; CURVED DNA; GAMMA INTERFERON;

ARTICLE; BINDING SITE; DNA FLANKING REGION; EPSTEIN BARR VIRUS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE HOMOLOGY; TRANSCRIPTION INITIATION; VIRUS LATENCY;

EID: 0031046602     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.2.873     Document Type: Article

References (101)

1. Abdulkadir, S. A., S. Krishna, D. Thanos, T. Maniatis, J. L. Strominger, and S. J. Ono. 1995. Functional roles or the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DR gene expression. J. Exp. Med. 182:487-500.
2. Altiok, E., J. Minarovits, H. Li-Fu, B. Contreras-Brodin, G. Klein, and I. Ernberg. 1992. Host-cell-phenotype-dependent control of BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc. Natl. Acad. Sci. USA 89:905-909.
3. Ambinder, R. F., W. A. Shah, D. R. Rawlins, G. S. Hayward, and S. D. Hayward. 1990. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in the Epstein-Barr virus DNA. J. Virol. 64:2369-2379.
4. Ben-Bassat, H., N. Goldblum, S. Mitrani, T. Goldblum, J. M. Yoffey, M. M. Cohen, Z. Bentwitch, B. Ramot, E. Klein, and G. Klein. 1977. Establishment in culture of a new type of lymphocyte from a "Burkitt-like" lymphoma (line D.G.-75). Int. J. Cancer 19:27-33.
5. Bovolenta, C., P. H. Driggers, M. S. Marks, J. A. Medin, A. D. Politis, S. N. Vogel, D. E. Levy, K. Sakaguchi, E. Appella, J. E. Coligan, and K. Ozato. 1994. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc. Natl. Acad. Sci. USA 91:5046-5050.
6. Chen, F., J.-Z. Zou, L. di Renzo, G. Winberg, L.-F. Hu, E. Klein, G. Klein, and I. Ernberg. 1995. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP-1. J. Virol. 69:3752-3758.
7. Dean, F. B., and M. O'Donnell. 1996. DNA-protein interactions: two steps to binding replication origins? Curr. Biol. 6:931-934.
8. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.
9. Du, W., and T. Maniatis. 1994. The high mobility group protein HMG I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms. Proc. Natl. Acad. Sci. USA 91:11318-11322.
10. Ernberg, I., K. Falk, J. Minarovits, P. Busson, T. Tursz, M. G. Masucci, and G. Klein. 1989. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J. Gen. Virol. 70: 2989-3002.
11. Falvo, J. V., D. Thanos, and T. Maniatis. 1995. Reversal of intrinsic DNA bends in the IFNβ gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83:1101-1111.
12. Flemington, E., and S. H. Speck. 1990. Identification of phorbol ester responsive elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226.
13. Flemington, E. K., J. P. Lytle, C. Cayrol, A. Borras, and S. H. Speck. 1994. DNA-binding-defcctive mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities. Mol. Cell. Biol. 14:3041-3052.
14. Genin, P., J. Braganca, N. Darracq, J. Doly, and A. Civas. 1995. A novel PRDI and TG binding activity involved in virus-induced transcription of IFN-α genes. Nucleic Acids Res. 23:5055-5063.
15. Goodbourn, S., H. Burstein, and T. Maniatis. 1986. The human β-interferon gene enhancer is under negative control. Cell 45:601-010.
16. Goodbourn, S., and T. Maniatis. 1988. Overlapping positive and negative regulatory domains of the human β-interferon gene. Proc. Natl. Acad. Sci. USA 85:1447-1451.
17. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
18. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
19. Harada, H., T. Fujita, M. Miyamoto, Y. Kimura, M. Maruyama, A. Furia, T. Miyata, and T. Taniguchi. 1989. Structurally similar but functionally distinct factors. IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58:729-739.
20. Harada, H., M. Kitagawa, N. Tanaka, H. Yamamoto, K. Harada, M. Ishihara, and T. Taniguchi. 1993. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259:971-974.
21. Jainchill, J. L., S. A. Aaronson, and G. J. Todaro. 1969. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J. Virol. 4:549-553.
22. Jansson, A., M. Masucci, and L. Rymo. 1992. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J. Virol. 66:62-69.
23. John, S., R. B. Reeves, J.-X. Lin, R. Child, J. M. Leiden, C. B. Thompson, and W. J. Leonard. 1995. Regulation of cell-type-specific interleukin-2 receptor α-chain gene expression: potential role of physical interactions between Elf-1, HMG-I(Y). and NF-κB family proteins. Mol. Cell. Biol. 15:1786-1796.
24. Jones, C. H., S. D. Hayward, and D. R. Rawlins. 1989. Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J. Virol. 63:101-110.
25. Kamijo, R., H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S. I. Koh, T. Kimura, S. L. Green, T. W. Mak, T. Taniguchi, and J. Vilcek. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263:1612-1615.
26. Keller, A. D., and T. Maniatis. 1991. Identification and characterization of a novel repressor of β-interferon gene expression. Genes Dev. 5:868-879.
27. Kerr, B. M., A. L. Lear, M. Rowe, D. Croom-Carter, L. S. Young, S. M. Rookes, P. H. Gallimore, and A. B. Rickinson. 1992. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187:189-201.
28. Kessler, D. S., S. A. Veals, X.-Y. Fu, and D. E. Levy. 1990. Interferon-α regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 4:1753-1765.
29. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.
30. b promoter: enhancer-like sequences and their role in the regulation of class I gene expression. Cell 44:261-272.
31. Klein, G., L. Dombos, and M. Gothosokar. 1972. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphohlastoid cell lines to superinfection with EB-virus. Int. J. Cancer 10:44-57.
32. Klein, G., B. Giovanella, A. Westman, J. S. Stehlin, and D. Mumford. 1975. An EBV-senome-negative cell line established from an American Burkitt lymphoma: receptor characteristics. EBV infectability and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5:319-334.
33. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:791-793.
34. Krek, W., D. M. Livingston, and S. Shirodokar. 1993. Binding to DNA and retinoblastoma gene product promoted by complex formation of different E2F family members. Science 262:1557-1560.
35. Lam, E. W., and N. B. La Thangue. 1994. DP and E2F proteins: coordinating transcription with cell cycle progression. Curr. Opin. Cell Biol. 6:859-866.
36. Leger, H., E. Sock, K. Renner, F. Grummt, and M. Wegner. 1995. Functional interaction between the POU domain protein Tst-1/Oct-6 and the high-mobility-group protein HMG-I/Y. Mol. Cell. Biol. 15:3738-3747.
37. Lenoir, G. M., M. Vuillaume, and C. Bonnardel. 1985. The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. IARC Sci. Publ. 60:309-318.
38. Lerman, M. I., A. Sakai, K. T. Yao, and N. H. Colburn. 1987. DNA sequences in human nasopharyngeal carcinoma cells that specify susceptibility to tumor promoter-induced neoplastic transformation. Carcinogenesis 8:121-127.
39. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688.
40. Levy, D. E., D. S. Kessler, R. Pine, N. Reich, and J. E. Darnell. 1988. Interferon-induced nuclear factors that bind to a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 2:381-393.
41. Liebowitz, D., and E. Kieff. 1993. Epstein-Barr virus, p. 107-172. In B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpes viruses. Raven Press, New York, N.Y.
42. Lozzio, C. B., and B. B. Lozzio. 1975. Human chrome myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45:321-334.
43. MacGregor, G. R., and C. T. Caskey. 1489. Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res. 17:2365.
44. Masucci, M. G., B. Contreras-Salazar, E. Ragnar, K. Falk, J. Minarovits, I. Ernberg, and G. Klein. 1989. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J. Virol. 63:3135-3141.
45. Matsuyama, T., T. Kimura, M. Kitagawa, K. Pfeffer, T. Kawakimi, M. Watanabe, T. M. Kundig, R. Amakawa, K. Kishihara, A. Wakeham, J. Potter, C. L. Furlonger, A. Narendran, H. Suzuki, P. S. Ohashi, C. J. Paige, T. Taniguchi, and T. W. Mak. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75:83-97.
46. Menezes, J., W. Liebold, G. Klein, and G. Clements. 1975. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (B-JAB) from an exceptional EBV-genome negative African Burkitt's lymphoma. Biomedicine 22:276-284.
47. Michael, S. F. 1994. Mutagenesis by incorporation of a phosphorylated oligo during PCR amplification. BioTechniques 16:410-412.
48. Min, W., J. S. Pober, and D. R. Johnson. 1996. Kinetically coordinated induction of TAP1 by IFN-γ: the rapid induction of TAP1 by IFN-γ is mediated by STAT1α. J. Immunol. 156:3174-3183.
49. Minarovits, J., L.-F. Hu, S. Minarovits-Kormuta, G. Klein, and I. Ernberg. 1994. Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP1 and BCR2 enhancer-promoter regions. Virology 200:661-667.
50. Miyamoto, M., T. Fujita, Y. Kimura, M. Maruyama, H. Harada, Y. Sudo, T. Miyata, and T. Taniguchi. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell 54:903-913.
51. Miyashita, E. M., B. Yang, K. M. C. Lam, D. H. Crawford, and D. A. Thorley-Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601.
52. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176: 157-168.
53. Neish, A. S., M. A. Read, D. Thanos, R. Pine, T. Maniatis, and T. Collins. 1995. Endothelial interferon regulatory factor 1 cooperates with NF-κB as a transcriptional activator of vascular cell adhesion molecule 1. Mol. Cell. Biol. 15:2558-2569.
54. Nelson, N., M. S. Marks, P. H. Driggers, and K. Ozato. 1993. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 13:588-599.
55. Nelson, N., Y. Kanno, C. Hong, C. Contursi, T. Fujita, B. J. Fowlkes, E. O'Connell, J. Hu-Li, W. E. Paul, D. Jankovic, A. F. Sher, J. E. Coligan, A. Thornton, E. Appella, Y. Yang, and K. Ozato. 1996. Expression of IFN regulatory factor family proteins in lymphocytes: induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J. Immunol. 156:3711-3720.
56. Neuman, E., E. K. Flemington, W. R. Sellers, and W. G. Kaelin, Jr. 1994. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14:6607-6615.
57. Nonkwelo, C., J. Skinner, A. Bell, A. Rickinson, and J. Sample. 1996. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70:623-627.
58. Pine, R., T. Decker, D. S. Kessler, D. E. Levy, and J. E. Darnell, Jr. 1990. Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon-and interferon-stimulated genes but is not a primary transcriptional activator of either. Mol. Cell. Biol. 10:2448-2457.
59. Porter, A. C. G., Y. Chernajovsky, T. C. Dale, C. S. Gilbert, G. R. Stark, and I. M. Kerr. 1988. Interferon response element of the human gene 6-16. EMBO J. 7:85-92.
60. Qu, L., and D. Rowe. 1992. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66:3715-3724.
61. Reeves, R., and A. P. Wolffe. 1996. Substrate structure influences binding of the non-histone protein HMG-I(Y) to free and nucleosomal DNA. Biochemistry 35:5063-5074.
62. Robertson, K. D., S. D. Hayward, P. D. Ling, D. Samid, and R. Ambinder. 1995. Transcriptional activation of Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol. Cell. Biol. 15:6150-6159.
63. Rooney, C. M., M. Rowe, L. E. Wallace, and A. B. Rickinson. 1985. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 317:629-631.
64. Rowe, D. T., M. Rowe, G. I. Evan, L. Wallace, P. J. Farrell, and A. B. Rickinson. 1986. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J. 5:2599-2607.
65. Ruffner, H., L. F. L. Reis, D. Naf, and C. Weissmann. 1993. Induction of type I interferon genes and interferon-inducible genes in embryonal stem cells devoid of interferon regulatory factor 1. Proc. Natl. Acad. Sci. USA 90:11503-11507.
66. Rutherford, M. N., G. E. Hannigan, and B. R. G. Williams. 1988. Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. EMBO J. 7:751-759.
67. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
68. Sample, J., E. B. D. Henson, and C. Sample. 1992. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 66:4654-4661.
69. Schaefer, B. C., M. Woisetschlaeger, J. L. Strominger, and S. H. Speck. 1991. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Nail. Acad. Sci. USA 88:6550-6554.
70. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group I Burkitt lymphoma cell lines. J. Virol. 69:5039-5047.
71. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. USA 92:10565-10569.
72. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1996. A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle. J. Virol. 70:8204-8208.
73. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1997. Host cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol. Cell. Biol. 17:364-377.
74. 73a. Schaefer, B. C., J. L. Strominger, and S. H. Speck. Unpublished data.
75. Shin, W. S., Y.-H. Hong, H.-B. Peng, R. De Caterina, P. Libby, and J. Liao. 1996. Nitric oxide attenuates vascular smooth muscle activation by interferon-γ: the role of constitutive NF-γB activity. J. Biol. Chem. 271:11317-11324.
76. Speck, S. H., and J. L. Strominger. 1989. Transcription of Epstein-Barr virus in latently infected, growth transformed lymphocytes. Adv. Viral Oncol. 8:133-150.
77. Sung, N. S., J. Wilson, M. Davenport, N. Sista, and J. S. Pagano. 1994. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Mol. Cell. Biol. 14:7144-7152.
78. Takada, K., K. Horinouchi, Y. Ono, T. Aya, M. Osato, M. Takahashi, and S. Hayasaka. 1991. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5:147-156.
79. Tamura, T., M. Ishihara, M. S. Lamphier, N. Tanaka, I. Oishi, S. Aizawa, T. Matsuyama, T. W. Mak, S. Taki, and T. Taniguchi. 1995. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376:596-599.
80. Tanaka, N., T. Kawakamai, and T. Taniguchi. 1993. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2. regulators of cell growth and the interferon system. Mol. Cell. Biol. 13:4531-4538.
81. Tanaka, N., M. Ishihara, M. Kitagawa, H. Harada, T. Kimura, T. Matsuyama, M. S. Lamphier, S. Aizawa, T. W. Mak, and T. Taniguchi. 1994. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77:829-839.
82. Taniguchi, T., H. Harada, and M. Lamphier. 1995. Regulation of the interferon system and cell growth by the IRF transcription factors. J. Cancer Res. Clin. Oncol. 121:516-520.
83. Thanos, D., and T. Maniatis. 1992. The high mobility group protein HMG I(Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell 71:777-789.
84. Thanos, D., and T. Maniatis. 1995. Identification of the rel family members required for virus induction of the human beta interferon gene. Mol. Cell. Biol. 15:152-164.
85. Thanos, D., and T. Maniatis. 1995. Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome. Cell 83:1091-1100.
86. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385.
87. van Wijnen, A. J., F. M. I. van den Ent, J. B. Lian, J. L. Stein, and G. S. Stein. 1992. Overlapping and CpG methylation-sensitive protein-DNA interactions at the histone H4 transcriptional cell cycle domain: distinctions between two human H4 gene promoters. Mol. Cell. Biol. 12:3273-3287.
88. van Wijnen, A. J., F. Aziz, X. Grana, A. De Luca, R. K. Desai, K. Jaarsveld, T. J. Last, K. Soprano, A. Giordano, J. B. Lian, J. L. Stein, and G. S. Stein. 1994. Transcription of histone H4, H3, and H1 cell cycle genes: promoter factor HiNF-D contains CDC2, cyclin A, and a RB-related protein. Proc. Natl. Acad. Sci. USA 91:12882-12886.
89. Vaughan, P. S., F. Aziz, A. J. van Wijnen, S. Wu, H. Harada, T. Taniguchi, K. Soprano, J. L. Stein, and G. S. Stein. 1995. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2. Nature 377:362-365.
90. Veals, S. A., T. Santa Maria, and D. E. Levy. 1993. Two domains of ISGF3γ that mediate protein-DNA and protein-protein interactions during transcription factor assembly contribute to DNA-binding specificity. Mol. Cell. Biol. 13:196-206.
91. Weis, L., and D. Reinberg. 1992. Transcription by RNA polymerase II: initiator-directed formation of transcription competent complexes. FASEB J. 6:3300-3309.
92. Weiss, A., R. L. Wiskocil, and J. D. Stobo. 1984. The role of T3 surface molecules in the activation of human T cells: a two stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol. 133:123-128.
93. Weisz, A., P. Marx, R. Sharf, E. Appella, P. H. Driggers, K. Ozato, and B.-Z. Levi. 1992. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J. Biol. Chem. 267:25589-25596.
94. Whitley, M. Z., D. Thanos, M. A. Read, T. Maniatis, and T. Collins. 1994. A striking similarity in the organization of the E-selectin and beta interferon gene promoters. Mol. Cell. Biol. 14:6464-6475.
95. Woisetschlaeger, M., J. L. Strominger, and S. H. Speck. 1989. Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proc. Natl. Acad. Sci. USA 86:6498-6502.
96. Woisetschlaeger, M., C. N. Yandava, L. A. Furmanski, J. L. Strominger, and S. H. Speck. 1990. Promoter switching in Epstein-Barr virus during the initial stages of infection. Proc. Natl. Acad. Sci. USA 87:1725-1729.
97. Wu, L., B. J. Morley, and R. D. Campbell. 1987. Cell-specific expression of the human complement protein factor B gene: evidence for the role of distinct 5′-flanking elements. Cell 48:331-342.
98. Yamamoto, H., M. S. Lamphier, T. Fujita, T. Taniguchi, and H. Harada. 1994. The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain. Oncogene 9:1423-1428.
99. Yates, J., N. Warren, D. Reisman, and B. Sugden. 1984. A cis-acting element from the Epstein-Barr virus genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. USA 81:3806-3810.
100. Yates, J., N. Warren, and B. Sugden. 1985. Plasmids derived from Epstein-Barr virus replicate stably in a variety of mammalian cells. Nature 313:812-815.
101. Zech, L., U. Haglund, K. Nilsson, and G. Klein. 1976. Characteristic chromosomal abnormalities in biopsies and lymphoid cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17:47-56.